AstraZeneca, SOPHiA team up to use AI, machine learning in cancer drugs development
Roland Magnusson/iStock Editorial via Getty Images


SOPHiA Genetics (NASDAQ:SOPH) is collaborating with AstraZeneca (NASDAQ:AZN) to apply its multimodal algorithmic capabilities to the British pharma giant's oncology portfolio.
The companies said the multimodal approach will go beyond a single data modality, combining radiomics analysis of medical imaging data, molecular data, digital pathology, clinical and biologic data for a assessment of multimodal signatures using AI and machine learning technology.

The companies will explore ways to accelerate trials, support evidence generation for market access, and improve clinical decision-making, to help clinicians select the best possible treatments.
The partnership will use SOPHiA DDM platform and multimodal algorithmic capabilities.
"Multimodality aims to harness the power of advanced AI and machine learning models by integrating multiple data modalities to obtain key insights which inform prognosis and response to therapy at the individual patient level," said Greg Rossi, senior vice president, Oncology Europe & Canada, AstraZeneca.